Extracorporeal membrane oxygenation for life-threatening asthma refractory to mechanical ventilation: analysis of the Extracorporeal Life Support Organization registry

Hye Ju Yeo1,2, Dohyung Kim2,3, Doosoo Jeon1,2, Yun Seong Kim1,2, Peter Rycus4 and Woo Hyun Cho1,2*

Abstract

Background: The use of extracorporeal membrane oxygenation (ECMO) in cases of near-fatal asthma (NFA) has increased, but the benefits and potential complications of this therapy have yet to be fully investigated.

Methods: Cases were extracted from the Extracorporeal Life Support Organization Registry between March 1992 and March 2016. All patients with a diagnosis of asthma (according to the International Classification of Diseases 9th edition), who also received ECMO, were extracted. Exclusion criteria included patients who underwent multiple courses of ECMO; those who received ECMO for cardiopulmonary resuscitation or cardiac dysfunction; and those with another primary diagnosis, such as sepsis. We analyzed survival to hospital discharge, complications, and clinical factors associated with in-hospital mortality, in patients with severe life-threatening NFA requiring ECMO support.

Results: In total 272 patients were included. The mean time spent on ECMO was 176.4 hours. Ventilator settings, including rate, fraction of inspired oxygen (FiO₂), peak inspiratory pressure (PIP), and mean airway pressure, significantly improved after ECMO initiation (rate (breaths/min), 19.0 vs. 11.3, p < 0.001; FiO₂ (%), 81.2 vs. 48.8, p < 0.001; PIP (cmH₂O), 38.2 vs. 25.0, p < 0.001; mean airway pressure (cmH₂O): 21.4 vs. 14.2, p < 0.001). In particular, driving pressure was significantly decreased after ECMO support (29.5 vs. 16.8 cmH₂O, p < 0.001). The weaning success rate was 86.7%, and the rate of survival to hospital discharge was 83.5%. The total complication rate was 65.1%, with hemorrhagic complications being the most common (28.3%). Other complications included renal (26.8%), cardiovascular (26.1%), mechanical (24.6%), metabolic (22.4%), infection (16.5%), neurologic (4.8%), and limb ischemia (2.6%). Of the hemorrhagic complications, cannulation site hemorrhage was the most common (13.6%). Using multivariate logistic regression analysis, it was found that hemorrhage was associated with increased in-hospital mortality (odds ratio, 2.97; 95% confidence interval, 1.07–8.24; p = 0.036). Hemorrhage-induced death occurred in four patients (1.5%). The most common reason for death was organ failure (37.8%).

(Continued on next page)
Background
Near-fatal asthma (NFA) is a life-threatening condition caused by acute respiratory failure, and is the most severe clinical presentation of asthma [1, 2]. Although there are no specific diagnostic criteria for NFA, it is characterized by cardiorespiratory arrest, hypercapnia, acidemia, and the need for intubation and mechanical ventilation [3]. NFA can progress to fatal asthma, and the mortality rate varies widely across countries. In 2015, there were 3615 deaths from asthma in the USA [4]. Despite recent advances in treatment, the mortality rate for asthma has not changed significantly. It may be that much of the current asthma mortality is due to unpredictable deaths in the context of NFA [5]. Globally, nearly 30% of NFA cases result in significant morbidity and mortality [4–10]. Traditionally, protective mechanical ventilation with rescue therapy, including neuromuscular blockade, has been the mainstay treatment for NFA. However, technical advances in extracorporeal membrane oxygenation (ECMO) have made it a promising alternative therapy in the treatment of life-threatening NFA [11–13].

ECMO can provide adequate gas exchange during acute respiratory failure, and can help prevent lung injury induced by aggressive mechanical ventilation. Using data from the multicenter Extracorporeal Life Support Organization (ELSO) Registry, a previous study showed that ECMO support improved survival in patients with status asthmaticus to a greater degree than in other respiratory conditions [11]. However, this study included a small number of cases. The low incidence of NFA may preclude large-scale, prospective randomized trials on the effectiveness of ECMO in this context. Nevertheless, an increasing number of reports suggest ECMO may be an effective rescue therapy for NFA [12, 13].

Despite the potential benefits of ECMO in NFA, concerns remain about complications. In general, complications are the primary factor limiting the effectiveness of ECMO in many diseases. Evidence supporting ECMO use in NFA is lacking, and questions about the safety and effectiveness of ECMO in NFA remain unanswered. In this study, we reviewed data from the ELSO Registry collected between March 1992 and March 2016. Our aim was to investigate survival to hospital discharge, complications, and clinical factors associated with inhospital mortality, in patients with severe life-threatening NFA requiring ECMO support.

Methods
The ELSO Registry is a worldwide voluntary registry. Currently, data are collected from 350 international ECMO centers. Data are collected using a standardized form, and include patient demographics, pre-ECMO ventilator settings, pre-ECMO arterial blood gas analysis (ABGA), post-ECMO ventilator settings, ECMO complications, and survival to hospital discharge [14]. Driving pressure (ΔP) was calculated as ventilator-measured plateau pressure minus applied positive end-expiratory pressure (PEEP). Diagnostic information is reported using the International Classification of Diseases 9th edition (ICD-9) codes, and indications for ECMO application are categorized as cardiac, respiratory, or extracorporeal cardiopulmonary resuscitation (ECPR). The study was approved by the Institutional Review Board (IRB) of Pusan National University Yangsan Hospital (IRB no.05-2017-066). Informed consent was not sought due to the retrospective nature of the study.

Patient cohorts
Between March 1992 and March 2016, 24,147 adults aged over 18 years were registered in the ELSO database. All cases of ECMO use in the context of an ICD-9 diagnosis of asthma were extracted (N = 568). Patients receiving ECMO support for ECPR or cardiac dysfunction were excluded according to the support type (ECPR, cardiac, or respiratory), and multiple ECMO courses were excluded. To discriminate between asthma and other non-asthmatic respiratory ECMO cases, patients with other primary diagnoses were also excluded. For example, a patient with asthma who received ECMO for sepsis was excluded, as sepsis was the primary indication for therapy. In total, 272 patients were included in the NFA group (Fig. 1).

Statistical analysis
Data were reported as mean values with standard deviations for normally distributed data, or frequencies with proportions for categorical data. We compared the demographics, pre-ECMO and post-ECMO values, and ECMO complications between survivors and non-survivors among patients with NFA. Student’s t test was used for continuous data and the Fisher’s exact or Pearson’s chi-square test was used for categorical data. Pre-ECMO and post-ECMO ventilator settings were compared using the paired t test.

Conclusions: ECMO can provide adequate gas exchange and prevent lung injury induced by mechanical ventilation, and may be an effective bridging strategy to avoid aggressive ventilation in refractory NFA. However, careful management is required to avoid complications.

Keywords: Extracorporeal Life Support Organization, Extracorporeal membrane oxygenation, Outcomes, Near-fatal asthma,
Binary logistic regression analysis was used to identify predictors of in-hospital mortality. Significant and borderline values \((\leq 0.05)\) were entered into stepwise backward multivariable logistic regression, including age as the continuous covariate, to estimate factors associated with mortality prior to hospital discharge. Two-way interaction terms were tested between the remaining significant variables. A \(p\) value <0.05 was considered significant. Age, pre-ECMO ventilator settings, pre-ECMO ABGA, post-ECMO ventilator settings, and ECMO complications were used as predictors.

**Results**

**Baseline patient characteristics**

Among the 24,147 adult patients in the ELSO registry, 568 patients had a diagnosis of asthma according to the ICD-9 code (2.4%). Of these, 272 patients met the criteria for inclusion in the study. The use of ECMO for NFA in adults has been growing rapidly since 1992 (Additional file 1). The baseline clinical characteristics of the patients are presented in Table 1. Mean age was 36.2 years (range, 18–83 years). Mean body weight was 88.0 kg and 39.7% of the patients were men. Pre-ECMO ABGA showed hypercapnic acidosis with mean pH of 7.1, mean partial pressure of carbon dioxide of 80.5 mmHg, and mean partial pressure of arterial oxygen/mean fraction of inspired oxygen (FiO\(_2\)) ratio of 153.7. The mean values of the ventilator settings were relatively high. Prior to ECMO initiation, the mean peak inspiratory pressure (PIP) was 38.2 cmH\(_2\)O; mean airway pressure was 21.4 cmH\(_2\)O; mean PEEP was 8.3 cmH\(_2\)O; mean FiO\(_2\) was 81.2%; and mean driving pressure was 29.2 cmH\(_2\)O.

**ECMO details**

Venovenous ECMO was the most common mode used (93.9%, Table 2). Double lumen cannulation was used in 43.5% of patients. The mean duration of ECMO support was 176.4 hours, and 63.2% (163/258) of patients were weaned off of ECMO within 7 days. Improvement was characterized using the best ventilator settings occurring within 24 hours of ECMO initiation. Mean FiO\(_2\) was 48.8%; mean PIP was 25.0 cmH\(_2\)O; the mean of the mean airway pressures was 14.2 cmH\(_2\)O; and the average driving pressure was 16.8 cmH\(_2\)O. Respiration rate, FiO\(_2\), PIP, and mean airway pressure significantly decreased within 24 hours of ECMO initiation (rate (breaths/min), 19.0 vs. 11.3, \(p<0.001\); FiO\(_2\) (%), 81.2 vs. 48.8, \(p<0.001\); PIP (cmH\(_2\)O), 38.2 vs. 25.0, \(p<0.001\); mean airway pressure (cmH\(_2\)O), 21.4 vs. 14.2, \(p<0.001\)). In particular, driving pressure was significantly decreased after ECMO support (29.5 vs. 16.8 cmH\(_2\)O, \(p<0.001\), Fig. 2).

**Complications and in-hospital mortality**

In-hospital complications are shown in Table 3 and Additional file 2. Complications occurred in 177 patients (65.1%). Hemorrhagic complications were the most common (28.3%, 77/272). Other complications included renal (26.8%, 73/272), cardiovascular (26.1%, 71/272), mechanical (24.6%, 67/272), and metabolic (22.4%, 61/272) complications, culture-proven infection (16.5%, 45/272), neurologic complications (4.8%, 13/272), and limb ischemia (2.6%, 7/272). Among the hemorrhagic complications, cannulation-site hemorrhage was the most common (13.6%, 37/272). Other hemorrhagic complications included surgical-site hemorrhage (8.5%), pulmonary hemorrhage (5.1%) and gastrointestinal hemorrhage (2.6%). There were four deaths due to hemorrhage (1.5%).

Overall, the rate of weaning success was 86.7% (234/272) and the rate of survival to discharge was 83.5% (227/272). Among non-survivors, 15.6% (7/45) died after ECMO weaning. The most common reason for death was organ failure (37.8%, 17/45; Additional file 2).
Table 1  Baseline patient characteristics

| Variables                  | Total  | Survivor  | Non-survivor | p    |
|----------------------------|--------|-----------|--------------|------|
| Age                        | 36.2 ± 13.4 | 34.7 ± 12.5 | 43.4 ± 15.8  | 0.001|
| Male, N (%)                | 108 (39.7) | 93 (40.9)  | 15 (33.3)    | 0.356|
| Weight, kg                 | 88.0 ± 29.1 | 87.5 ± 28.9 | 90.9 ± 30.4  | 0.501|
| Pre-ECMO blood gases⁴      |        |           |              |      |
| pH                         | 7.1 ± 0.2 | 7.1 ± 0.2  | 7.2 ± 0.2    | 0.045|
| PCO₂, mmHg                 | 80.5 ± 50.6 | 81.1 ± 51.6 | 77.2 ± 45.5  | 0.638|
| HCO₃⁻, mmol/L             | 29.0 ± 9.4 | 29.2 ± 9.4  | 27.8 ± 9.6   | 0.402|
| SaO₂, %                    | 91.2 ± 10.1 | 92.3 ± 7.4  | 85.2 ± 17.3  | 0.030|
| Pre-ECMO ventilator setting|        |           |              |      |
| Rate, breaths/min          | 19.0 ± 7.7 | 18.6 ± 7.4  | 21.4 ± 9.4   | 0.129|
| FiO₂, %                    | 81.2 ± 23.0 | 80.2 ± 23.2 | 87.2 ± 21.1  | 0.105|
| PIP, cmH₂O                 | 38.2 ± 11.1 | 38.1 ± 11.4 | 38.7 ± 9.1   | 0.798|
| PEEP, cmH₂O               | 8.3 ± 5.9  | 7.8 ± 5.9   | 11.5 ± 5.1   | 0.002|
| MAP, cmH₂O                | 21.4 ± 14.2 | 21.4 ± 15.1 | 21.3 ± 7.8   | 0.980|
| Driving pressure, cmH₂O    | 29.5 ± 12.9 | 29.9 ± 13.4 | 27.4 ± 9.5   | 0.363|

Values are shown as number (%) or mean ± SD
ECMO extracorporeal membrane oxygenation, FiO₂ fraction of inspired oxygen saturation, HCO₃⁻ arterial bicarbonate level, MAP mean airway pressure, PEEP positive end-expiratory pressure, PIP peak inspiratory pressure, PO₂ partial pressure of arterial oxygen, SaO₂ arterial oxygen saturation
⁴The worst values in the previous 6 h were collected

Table 2  Clinical parameters related to mechanical ventilation and extracorporeal membrane oxygenation support

| Variables                  | Total  | Survivor  | Non-survivor | p    |
|----------------------------|--------|-----------|--------------|------|
| ECMO mode⁵                 |        |           |              |      |
| V                          | 131 (50.4) | 110 (50.7) | 21 (48.8)    | 0.824|
| VDL                        | 113 (43.5) | 94 (43.3)  | 19 (44.2)    | 0.916|
| W to VA                    | 3 (1.2)  | 1 (0.5)   | 2 (4.7)      | 0.019|
| VA                         | 5 (1.9)  | 5 (2.3)   | 0            | 0.315|
| VDL + V                   | 6 (2.3)  | 5 (2.3)   | 1 (2.3)      | 0.993|
| Other                      | 2 (0.8)  | 2 (9.2)   | 0            | 0.527|
| Hours on ECMO              | 176.4 ± 192.7 | 161.6 ± 172.1 | 257.2 ± 268.4 | 0.035|
| Post-ECMO ventilator setting|        |           |              |      |
| Rate, breaths/min          | 11.3 ± 4.3 | 11.1 ± 4.2  | 12.7 ± 5.0   | 0.043|
| FiO₂, %                    | 488 ± 19.0 | 474 ± 17.8  | 574 ± 23.6   | 0.025|
| PIP, cmH₂O                 | 25.0 ± 7.8 | 24.3 ± 4.5  | 29.7 ± 8.3   | < 0.001|
| PEEP, cmH₂O               | 8.1 ± 4.5  | 7.9 ± 4.5   | 9.0 ± 4.0    | 0.195|
| MAP, cmH₂O                | 14.2 ± 10.0 | 14.2 ± 10.4 | 14.6 ± 6.2   | 0.866|
| Driving pressure, cmH₂O    | 16.8 ± 7.8 | 16.2 ± 7.8  | 21.1 ± 6.6   | 0.002|

Values are shown as number (%) or mean ± SD
ECMO extracorporeal membrane oxygenation, FiO₂ fraction of inspired oxygen saturation, HCO₃⁻ arterial bicarbonate level, MAP mean airway pressure, PEEP positive end-expiratory pressure, PIP peak inspiratory pressure, PO₂ partial pressure of arterial oxygen, SaO₂ arterial oxygen saturation, W venovenous, VDL venovenous double lumen, VA venoarterial, VDL + V double lumen venovenous ECMO with a cephalic draining cannula
⁵Available in 260 patients
⁶The best values in the last 24 h were collected
Differences between survivors and non-survivors

Baseline ECMO patient profiles were significantly different between survivors and non-survivors (Table 1). The mean age was lower in survivors (34.7 vs. 43.4, \( p = 0.001 \)), as was the mean pH (7.1 vs. 7.2, \( p = 0.045 \)). Saturation was higher in survivors (92.3 vs. 85.2, \( p = 0.030 \)). In addition, PEEP was lower in survivors (7.8 vs. 11.5, \( p = 0.002 \)).

ECMO duration and ventilator settings after ECMO initiation were significantly different between survivors and non-survivors (Table 2). The mean duration of ECMO was shorter in survivors (161.6 vs. 257.2, \( p = 0.035 \)). The values of rate, \( \text{FiO}_2 \), PIP, and driving pressure after ECMO initiation were lower in survivors (rate (breaths/min), 11.1 vs. 12.7, \( p = 0.043 \); \( \text{FiO}_2 \) (%), 47.4 vs. 57.4, \( p = 0.025 \); PIP).

Table 3 Complications and outcomes during extracorporeal membrane oxygenation support

| Variables                     | Total   | Survivor N = 227 | Non-survivor N = 45 | p      |
|-------------------------------|---------|-----------------|---------------------|--------|
| Mechanical                    | 67 (24.6) | 48 (21.1)       | 19 (42.2)           | 0.003  |
| Oxygenator failure            | 14 (5.1)  | 7 (3.1)         | 7 (15.6)            | 0.001  |
| Clots: oxygenator             | 31 (11.4) | 26 (11.5)       | 5 (11.1)            | 0.947  |
| Clots: other                  | 10 (3.7)  | 6 (2.6)         | 4 (8.9)             | 0.042  |
| Cannula problems              | 12 (4.4)  | 9 (4.0)         | 3 (6.7)             | 0.304  |
| Total bleeding                | 77 (28.3) | 52 (22.9)       | 25 (55.6)           | < 0.001|
| GI hemorrhage                 | 7 (2.6)   | 5 (2.2)         | 2 (4.4)             | 0.386  |
| Cannulation site bleeding     | 37 (13.6) | 25 (11.0)       | 12 (26.7)           | 0.005  |
| Surgical site bleeding        | 23 (8.5)  | 16 (7.0)        | 7 (15.6)            | 0.061  |
| Pulmonary hemorrhage          | 14 (5.1)  | 7 (3.1)         | 7 (15.6)            | 0.001  |
| Neurologic                    | 13 (4.8)  | 9 (4.0)         | 4 (8.9)             | 0.157  |
| Brain death                   | 6 (2.2)   | 3 (1.3)         | 3 (6.7)             | 0.026  |
| Seizures                      | 7 (2.6)   | 6 (2.6)         | 1 (2.2)             | 0.871  |
| Cerebral infarction           | 8 (2.9)   | 2 (0.9)         | 6 (13.3)            | < 0.001|
| Cerebral hemorrhage           | 12 (4.4)  | 7 (3.1)         | 5 (11.1)            | 0.017  |
| Renal                         | 73 (26.8) | 55 (24.2)       | 18 (40)             | 0.029  |
| Dialysis required             | 54 (19.9) | 39 (17.2)       | 15 (33.3)           | 0.013  |
| Cardiovascular                | 71 (26.1) | 57 (25.1)       | 14 (31.1)           | 0.402  |
| Infection culture proven      | 45 (16.5) | 34 (15.0)       | 11 (24.4)           | 0.118  |
| Pneumothorax requiring treatment | 14 (5.1) | 12 (5.3)        | 2 (4.4)             | 0.815  |
| Metabolic                     | 61 (22.4) | 50 (22.0)       | 11 (24.4)           | 0.722  |
| Limb ischemia                 | 7 (2.6)   | 5 (2.2)         | 2 (4.4)             | 0.386  |
| Total complication            | 177 (65.1)| 138 (60.8)      | 39 (86.7)           | 0.001  |
| Weaning success               | 234 (86.7)| 227 (100)       | 7 (15.6)            | < 0.001|

Values are shown as number (%) or mean ± SD

ECMO extracorporeal membrane oxygenation, GI gastrointestinal
(cmH$_2$O), 24.3 vs. 29.7, $p<0.001$; driving pressure (cmH$_2$O), 16.2 vs. 21.1, $p=0.002$).

The complication rate was higher in non-survivors (60.8 vs. 86.7, $p=0.001$; Table 3). The rate of mechanical complications was also higher in non-survivors (21.1 vs. 42.2, $p=0.003$), especially the rate of oxygenator failure (3.1 vs. 15.6, $p=0.001$) and clots (0.4 vs. 8.9, $p=0.042$). The rate of hemorrhage in general (22.9 vs. 55.6, $p=0.001$), the rate of cannulation-site hemorrhage (11.0 vs. 26.7, $p=0.005$), and the rate of pulmonary hemorrhage (3.1 vs. 15.6, $p=0.001$) were higher in non-survivors. Among neurologic complications, the rates of brain death (1.3 vs. 6.7, $p=0.026$), cerebral infarction (0.9 vs. 13.3, $p<0.001$), and cerebral hemorrhage (3.1 vs. 11.1, $p=0.017$) were higher in non-survivors. In addition, renal complications occurred more often in non-survivors (24.2% vs. 40%, $p=0.029$), especially the rate of dialysis (17.2 vs. 40, $p=0.013$).

**Factors associated with in-hospital mortality**

Univariate and multivariate analyses were performed to investigate the possible predictors of in-hospital mortality in the study population (Table 4). In the univariate analysis, age (odds ratio (OR), 1.05, 95% confidence interval (CI), 1.02–1.07, $p<0.001$), mechanical complication (OR, 2.73, 95% CI, 1.39–5.34, $p=0.003$), hemorrhage (OR, 4.21, 95% CI 2.16–8.18, $p<0.001$), dialysis on ECMO (OR, 2.41, 95% CI, 1.19–4.90, $p=0.015$), pre-ECMO PEEP (OR, 1.10, 95% CI, 1.03–1.18, $p=0.003$), pre-ECMO pH (OR, 7.57, 95% CI, 1.04–55.29, $p=0.046$), post-ECMO FiO$_2$ (OR, 1.02, 95% CI, 1.01–1.04, $p=0.006$), post-ECMO PIP (OR, 1.08, 95% CI, 1.03–1.14, $p=0.001$), and post-ECMO driving pressure (OR, 1.08, 95% CI, 1.03–1.13, $p=0.003$) were associated with increased in-hospital mortality. Among hemorrhagic complications, cannulation-site hemorrhage (OR, 2.94, 95% CI, 1.35–6.41, $p=0.007$), central nervous system hemorrhage (OR, 3.93, 95% CI, 1.19–12.99, $p=0.025$), and pulmonary hemorrhage (OR, 5.79, 95% CI, 1.92–17.44, $p=0.002$) were associated with increased in-hospital mortality.

In the multivariate logistic regression model, age (OR, 1.05, 95% CI, 1.01–1.08, $p=0.012$), bleeding (OR, 2.97, 95% CI, 1.07–8.24, $p=0.036$), pre-ECMO PEEP (OR, 1.10, 95% CI, 1.01–1.20, $p=0.027$), post-ECMO FiO$_2$ (OR, 1.03, 95% CI, 1.00–1.05, $p=0.034$), and post-ECMO driving pressure (OR, 1.08, 95% CI, 1.02–1.15, $p=0.011$) were associated with increased in-hospital mortality.

**Discussion**

To our knowledge, this is the largest study of patients who have received ECMO for NFA refractory to mechanical ventilation. In this study, ventilator settings significantly improved after ECMO initiation to allow protective ventilation. Overall survival to hospital discharge was 83.5%, which was favorable compared to the ECMO outcome of other types of respiratory failure. Otherwise, ECMO complication was still common, even though it was mostly not serious. The total complication rate was 65.1%, with hemorrhagic complications being the most common (28.3%). Although bleeding was associated with increased in-hospital mortality, fatal bleeding only occurred in 1.5% of cases and most other complications were not fatal. Therefore, ECMO may be an effective treatment to prevent ventilator-induced lung injury in NFA refractory to mechanical ventilation. In addition, careful monitoring is required to detect and manage complications early and reduce their impact.

The mortality rate of patients with asthma is decreasing, but remains significant [9, 10]. While mechanical ventilation is a potentially life-saving intervention, a large proportion of the morbidity and mortality seen in patients with asthma may be related to the mechanical ventilation itself.

**Table 4** Odds ratios of mortality at discharge

| Variables | Univariate analysis | Multivariate analysis |
|-----------|---------------------|----------------------|
| OR (95% CI) | $p$ | OR (95% CI) | $p$ |
| Age | 1.05 (1.02–1.07) | $<0.001$ | 1.05 (1.01–1.08) | 0.012 |
| Mechanical complications | 2.73 (1.39–5.34) | 0.003 | | |
| Bleeding | 4.21 (2.16–8.18) | $<0.001$ | 2.97 (1.07–8.24) | 0.036 |
| Dialysis | 2.41 (1.19–4.90) | 0.015 | | |
| Pre-ECMO PEEP, cmH$_2$O | 1.10 (1.03–1.18) | 0.003 | 1.10 (1.01–1.20) | 0.027 |
| Pre-ECMO pH | 7.57 (1.04–55.29) | 0.046 | | |
| Post-ECMO FiO$_2$, % | 1.02 (1.01–1.04) | 0.006 | 1.03 (1.00–1.05) | 0.034 |
| Post-ECMO PIP, cmH$_2$O | 1.08 (1.03–1.14) | 0.001 | | |
| Post-ECMO driving pressure, cmH$_2$O | 1.08 (1.03–1.13) | 0.003 | 1.08 (1.02–1.15) | 0.011 |

OR Odds ratio, CI confidential interval, ECMO extracorporeal membrane oxygenation, PEEP positive end-expiratory pressure, FiO$_2$ fraction of inspired oxygen saturation, PIP peak inspiratory pressure

*The worst values in the previous 6 h were collected

*The best values in the last 24 h were collected
Hemorrhage was the most common complication, even those unrelated to ECMO, such as hyperglycemia. The total complication rate included all minor complications, were lower than in previous studies [9]. However, the need for ECMO support may be required to prevent hemorrhage. Fortunately, ECMO stabilizes platelet function and the risk of hemorrhage is low in the early period of administration [27]. Furthermore, there is a recent trend toward conservative anticoagulation management. Clinicians should assess patient risk factors for ECMO-related hemorrhage, and actively take steps to correct them. In selected cases, termination of ECMO support may be required to prevent hemorrhage. The need for ECMO support should be reassessed when hemorrhagic complications are likely to be fatal.

This study had several limitations. First, we analyzed data voluntarily submitted by various international centers; these data may be susceptible to information bias, reporting bias, and uncontrolled confounding factors. Second, we defined patients with NFA as those with a primary ICD-9 diagnosis code of asthma. This may limit the applicability of these results to certain cases. Third, the ABGA values following ECMO initiation were not always present in this dataset, and as such their improvement could not be assessed as a secondary outcome. Furthermore, many of the baseline ventilator settings in this dataset did not adhere to the generally recommended criteria [21]. In these cases, refractory airway obstruction and unstable blood gas profiles might be related to suboptimal ventilator strategies. While this registry may not be representative of all cases, the strength of this study was that cases were extracted from a relatively large, international dataset. The data are also contemporary and reflect the current status of ECMO use in NFA. A further strength of the study was that the detailed complication profiles are present in the ELSO data. Because asthma is a reversible disease, it is important to know the complications associated with therapeutic interventions. This analysis provides important and current information to guide a rapid increase in the use of ECMO in NFA.
Conclusions
The management of NFA remains a significant problem in critical care. Mechanical ventilation of patients with NFA is challenging, and high ventilator settings may cause lung injury and hemodynamic instability secondary to barotrauma and dynamic hyperinflation. As NFA is ultimately reversible, clinicians should actively consider ECMO to both provide adequate gas exchange and prevent lung injury. In this study, ECMO provided full respiratory support in patients with NFA, and its use resulted in acceptable survival to hospital discharge. However, ECMO-related complications are common. To encourage the use of ECMO as a rescue therapy, understanding and reducing ECMO-related complications should be a priority. The use of ECMO to reduce ventilator-induced lung injury may reduce overall NFA mortality worldwide. Further clinical research into the use of ECMO in this context is needed.

Additional files

**Additional file 1: Figure S1.** This graph shows the increasing trend in extracorporeal membrane oxygenation use in adults with near-fatal asthma. (TIFF 80 kb)

**Additional file 2: Table S1.** Complications. Table S2. Reason for extracorporeal membrane oxygenation discontinuation and mortality. (DOC 80 kb)

Abbreviations

ABGA: Arterial blood gas analysis; ECMO: Extracorporeal membrane oxygenation; ECP: Extracorporeal cardiopulmonary resuscitation; ELSO: Extracorporeal Life Support Organization; FiO2: Fraction of inspired oxygen; ICD-9: International Classification of Diseases 9th edition; NFA: Near-fatal asthma; PEEP: Positive end-expiratory pressure; PIP: Peak inspiratory pressure; VV: Venovenous

Acknowledgements

We truly appreciate Peter Rycus, MPH, who had contributed in the acquisition of data from Extracorporeal Life Support Organization (ELSO) database.

Funding

No funding to declare.

 Availability of data and materials

Not applicable.

Authors’ contributions

Study concept and design: YHJ, CWH, KDH. Acquisition of data: PR. Analysis and interpretation of data: YHJ, CWH. Writing of the manuscript: YHJ, CWH. Critical revision of the manuscript: JD, CWH, KYS. Support for data collection: KDH. Approval of final manuscript and agreement of submission: all authors.

Authors’ information

Not applicable.

Ethics approval and consent to participate

The study was approved by the Institutional Review Board of Pusan National University Yangsan Hospital (IRB no.05-2017-066). Informed consent was not sought due to the retrospective nature of the study.

Consent for publication

Not applicable.

---

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1Department of Pulmonology and Critical Care Medicine, Pusan National University Yangsan Hospital, Geumo-ro 20, Beomneow-ri, Mulgeum-eup, Yangsan-si, Gyeongsangnam-do 50612, Republic of Korea. 2Research Institute for Convergence of Biomedical Science and Technology Pusan National University Yangsan Hospital, Yangsan, Republic of Korea. “Department of Thoracic and Cardiovascular Surgery, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea. "Extracorporeal Life Support Organization (ELSO), Ann Arbor, MI, USA.

Received: 30 July 2017 Accepted: 6 November 2017

Published online: 06 December 2017

References

1. McFadden Jr ER. Acute severe asthma. Am J Respir Crit Care Med. 2003;168:740–59.
2. Dhuper S, Maggiore D, Chung V, Shim C. Profile of near-fatal asthma in an inner-city hospital. Chest. 2003;124:1880–4.
3. Rodrigo GJ, Rodrigo C, Nannini L. Fatal or near-fatal asthma: clinical entity or incorrect management? Arch Bronconeumol. 2004;40:24–33.
4. CDC: Most recent asthma data. National data/state or territory data. 2015. https://www.cdc.gov/asthma/most_recent_data.htm. Accessed 18 July 2017.
5. Ebmeier S, Thayabaran D, Brathwaite L, et al. Trends in international asthma mortality: analysis of data from the WHO mortality database from 46 countries (1993-2012). Lancet. 2017;390:935–45.
6. Restrepo RD, Peters J. Near-fatal asthma: recognition and management. Curr Opin Pulm Med. 2008;14:13–23.
7. D’Amato G, Vitale C, Molino A, et al. Asthma-related deaths. Multidiscip Respir Med. 2016;11:37.
8. Al-Dorzi HM, Al-Shammary HA, Al-Shareef SY, et al. Risk factors, management and outcomes of patients admitted with near fatal asthma to a tertiary care hospital in Riyadh. Ann Thorac Med. 2014;9:33–8.
9. Bellido Casado J, Plaza V, Bardagi S, et al. Is the incidence of near-fatal asthma decreasing in Spain? Arch Bronconeumol. 2006;42:522–5.
10. Vianello A, Caminati M, Crivellaro M, et al. Fatal asthma: is it still an epidemic? World Allergy Organ J. 2016;9:42.
11. Mikkelsen ME, Woo YI, Sager JS, Fuchs BD, Christie JD. Outcomes using extracorporeal life support for adult respiratory failure due to status asthmaticus. ASAIO. 2009;55:47–52.
12. Steinack C, Lenherr R, Hendra H, Franzén D. The use of life-saving extracorporeal membrane oxygenation (ECMO) for pregnant woman with status asthmaticus. J Asthma. 2017;54:484–8.
13. Di Lascio G, Prifti E, Messal E, et al. Extracorporeal membrane oxygenation support for life-threatening acute severe status asthmaticus. Perfusion. 2017;32:157–63.
14. The Extracorporeal Life Support Organization registry support documents. https://www.elso.org/Registry/SupportDocuments/ECLSComplicationsCode.aspx. Accessed 18 July 2017.
15. Darioli R, Perret C. Mechanical controlled hypoventilation in status asthmaticus. Am Rev Respir Dis. 1984;129:385–7.
16. Anzueto A, Frutos-Vivar F, Esteban A, et al. Incidence, risk factors and outcome of barotrauma in mechanically ventilated patients. Intensive Care Med. 2004;30:612.
17. Hoddler R, Lougheed MD, FitzGerald JM, Rowe BH, Kaplan AG, McEvoy RA. Management of acute asthma in adults in the emergency department: assisted ventilation. CMAJ. 2010;182:265–72.
18. Schatz M, Kazzi AA, Brenner B, et al. Joint task force report: supplemental recommendations for the management and follow-up of asthma exacerbations. Introduction J Allergy Clin Immunol. 2009;124:51–4.
19. Georgopoulos D, Kondili E, Prinianakis G. How to set the ventilator in asthma. Archivio Monaldi per le malattie del torace. 2000;55:74–83.
20. Khawaja A, Shahzad H, Kazmi M, Zubairi AB. Clinical course and outcome of acute severe asthma (status asthmaticus) in adults. J Pak Med Assoc. 2014;64:1,292–6.
21. Holley AD, Boots RJ. Review article: management of acute severe and near-fatal asthma. EMA. 2009;21:259–68.
22. Amato MB, Meade MO, Slutsky AS, et al. Driving pressure and survival in the acute respiratory distress syndrome. N Engl J Med. 2015;372:747–55.
23. Loring SH, Malhotra A. Driving pressure and respiratory mechanics in ARDS. N Engl J Med. 2015;372:776–7.
24. Hye J, Dohyun K, Doosoo J, Yun Seong K, Woo HC. Low-dose heparin during extracorporeal membrane oxygenation treatment in adults. Intensive Care Med. 2015;41:2020–1.
25. Anne M. Winkler. Managing the precarious hemostatic balance during extracorporeal life support: implications for coagulation laboratories. Semin Thromb Hemost. 2017;43:291-9.
26. Christopher Lots, Nils Streiber, Norbert Roewer, et al. Therapeutic interventions and risk factors of bleeding during extracorporeal membrane oxygenation. ASAIO J. 2017;63:624-30.
27. Chung JH, Yeo HJ, Kim D, et al. Changes in the levels of beta-thromboglobulin and inflammatory mediators during extracorporeal membrane oxygenation support. Int J Artif Organs. 2017;40(10):575–80.
28. Sy E, Sklar MC, Lequier I, Fan E, Kanji HD. Anticoagulation practices and the prevalence of major bleeding, thromboembolic events, and mortality in venaarterial extracorporeal membrane oxygenation: A systematic review and meta-analysis. J Crit Care. 2017;39:87–96.